• Microbot Medical scheduled analyst and investor call for May 18 at 3:00 pm ET to address what it described as misleading statements in an unaffiliated third-party article about its LIBERTY endovascular robotic system.
• Management plans to review recent progress on full market release of LIBERTY, then correct what it called misrepresentations to ensure investors have accurate product and company information.
• Vascular surgeon Charles Briggs, a LIBERTY user at Tampa General Hospital, will discuss his experience with system, then address inaccuracies the company said were attributed to him in the article.
• Interventional radiologist Zachary L. Bercu of Emory Healthcare, described as first LIBERTY user, will also join call to discuss use of system in routine practice.
• Microbot cited a Wall Street research report that it said refuted claims in the article, including comments attributed to a vascular surgeon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150956PRIMZONEFULLFEED9721273) on May 15, 2026, and is solely responsible for the information contained therein.